托法替尼
医学
生物仿制药
类风湿性关节炎
贾纳斯激酶
Janus激酶抑制剂
鲁索利替尼
不利影响
第一行
临床试验
重症监护医学
安全概况
内科学
细胞因子
骨髓
骨髓纤维化
作者
Roberto Caporali,Sabino Germinario,Dorottya Kacsándi,Ernest Choy,Zoltán Szekanecz
标识
DOI:10.1016/j.autrev.2023.103429
摘要
Janus Kinase inhibitors (JAKis) have been approved for the treatment of Rheumatoid Arthritis (RA) for several years. They are the first oral advanced treatments with efficacy similar to, if not, greater than biologic agents. Recently, concern over their safety was raised by the results from Oral Surveillance trial suggesting that tofacitinib, one of the JAKis was associated with higher cardiovascular adverse events and malignancies than TNF inhibitors. Since then, regulatory authorities have added warnings the labels of JAKis. Should Rheumatologists use JAKis as first line advance treatment has become a controversial topic. Some rheumatologists have argued that biologics should be first line advance treatment since there are extensive effectiveness and safety data. In addition, with the advent of biosimilars, they are the most cost-effective treatment. On the other hand, JAKis are very efficacious and are generally safe apart from older and high-risk patients. When TNF inhibitors are contraindicated and in certain RA patients especially when an oral drug is preferable, JAKis have significant advantage providing patients are involved in the decision-making process.
科研通智能强力驱动
Strongly Powered by AbleSci AI